JW Pharmaceutical Files for Phase 3 Trial of Biweekly Obesity Drug Candidate
JW Pharmaceutical has moved a step closer to developing a next-generation obesity treatment with a less frequent dosing schedule.The company said Tuesday that it has submitted an Investigational New Drug (IND) application to South Korea’s Ministry of Food and Drug Safety for a Phase 3 clinical trial
JW Pharmaceutical has submitted an IND application to South Korea's Ministry of Food and Drug Safety for a Phase 3 clinical trial of bofanglutide, an obesity treatment candidate. The Korean trial, set to begin in December, will enroll 300 obese or overweight adults and run through March 2029, evaluating the drug's efficacy and safety against placebo.
Bofanglutide, licensed from China's Gan & Lee Pharmaceuticals, targets GLP-1 receptors to stimulate insulin secretion and slow gastric emptying, promoting satiety and weight loss. Its standout feature is a biweekly dosing schedule, potentially reducing annual injections from 52 to 26. Preliminary Phase 3 data from China showed 15.12% and 18.54% weight loss in 24 mg and 48 mg groups, respectively, with favorable tolerability.
As the global obesity-drug market grows more competitive, JW Pharmaceutical will use the Korean trial to confirm bofanglutide's benefits and safety in local patients and explore further trials for other metabolic disease indications.
Written by urgent.news from Korea IT Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
